查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2040642

日本陣發性睡眠性血尿症治療市場規模、佔有率和趨勢分析報告：按作用機制、給藥途徑、最終用途、地區和細分市場預測（2026-2033 年）

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Action of Mechanism, By Route of Administration, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

日本陣發性睡眠性血尿症治療市場概況

2025 年日本陣發性睡眠性血尿症治療市場價值 2.7995 億美元，預計到 2033 年將達到 4.5553 億美元，2026 年至 2033 年的複合年成長率為 5.88%。

這一成長得益於補體抑制療法的不斷進步，包括下一代 C3 和因子 B/D 抑制劑的開發，這些抑制劑可以改善臨床結果並解決殘餘貧血等未滿足的需求。

此外，日本健全的健保報銷政策和對孤兒藥的優惠待遇，有助於病患獲得高成本治療方法，並促進製藥業的創新。疾病認知度的提高和診斷能力的提升也有助於疾病的早期發現和治療，進一步擴大了符合治療條件的患者群體，並維持了市場成長。

該市場的主要驅動力是補體抑制療法的顯著進步，這些療法直接針對補體依賴性溶血的潛在機制。從輸血和抗凝血劑等支持性療法轉向標靶生物製藥，大大改變了臨床療效。 2026年2月發表於《國際血液學雜誌》（International Journal of Hematology）的真實世界臨床數據突顯了這項變化。在該研究中，45名日本患者中有86.7%接受了C5抑制劑治療，治療期間血紅素水平中位數從診斷時的7.2 g/dL升高至10.0 g/dL。

隨著第一代C5抑制劑向下一代治療方法的演進，包括針對C3和替代途徑因子的上游補體抑制劑，市場創新正在不斷增強。這些進展滿足了傳統治療方法中尚未滿足的需求：與血管外溶血相關的殘餘性貧血。 2025年9月發表在《Drugs》雜誌上的一篇綜述重點介紹了一項涉及441名患者的III期臨床試驗數據，結果顯示，在26週和52週時，lavlizumab的療效不劣於Eculizumab。此外，APPLY-PNH和APPOINT-PNH試驗的結果表明，與持續抗C5治療相比，口服iptacopan可使溶血標記持續降低，並改善血紅蛋白水平，這表明治療方案正朝著更具包容性和患者友好性的方向發展。

日本健全的醫療保健體系在市場擴張中發揮著至關重要的作用，尤其體現在其全民健保制度和扶持孤兒藥的政策上。政府的報銷計畫涵蓋約70%的醫療費用，確保了患者能夠廣泛獲得昂貴的生物製藥，並促進早期治療。監管支持進一步加速了創新，孤兒藥的優先審查期約為9個月，而標準審查期為12個月。這些獎勵吸引了國內外企業，形成了強大的先進治療方法研發管線，並鞏固了日本作為孤兒病治療藥物研發主要市場的地位。

診斷率的提高和公眾對該疾病認知度的提升也顯著促進了市場成長。高靈敏度流式細胞技術的廣泛應用和診斷方案的標準化正在加速陣發性睡眠性血紅蛋白尿症（PNH）的早期發現，尤其是在伴有再生障礙性貧血的患者中。 2024年10月出版的MDPI報告指出，40%至60%的患者體內檢測到了PNH克隆，未經治療的五年死亡率超過35%，凸顯了早期診斷的重要性。此外，2024年3月出版的《國際血液學雜誌》發表了一項針對59名接受C5抑制劑治療的日本患者的研究，結果顯示患者平均血紅蛋白水平為10.2 g/dL，顯示患者症狀負擔依然沉重，需要持續最佳化治療方案。這些因素共同推動了PNH診斷患者數量的增加，並促進了日本PNH治療市場的長期持續成長。

目錄

第1章：日本陣發性睡眠性血尿症治療市場：調查方法與範圍

第2章：日本陣發性睡眠性血尿症治療市場：執行摘要

  • 市場概覽
  • 作用機轉概述
  • 給藥途徑概述
  • 最終用途概述
  • 競爭格局概述

第3章：日本陣發性睡眠性血尿症治療市場：變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場譜系展望
  • 市場動態
  • 市場動態分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTEL 分析
  • 管道分析

第4章：日本陣發性睡眠性血尿症治療市場：作用機轉評估及趨勢分析

  • 日本陣發性睡眠性血尿症治療市場：作用機轉概覽
  • 日本陣發性睡眠性血尿症治療市場：作用機轉變化分析
  • 日本陣發性睡眠性血尿症治療市場：依治療方法及銷售收入分類
  • 補體抑制劑
    • C5抑制劑
    • C3抑制劑
  • 支持性護理
    • 輸血
    • 免疫抑制劑
    • 抗凝血物
    • 其他
  • 其他

第5章：日本陣發性睡眠性血尿症治療市場：依給藥途徑分類的估算與趨勢分析

  • 日本陣發性睡眠性血尿症治療市場：依給藥途徑分類的概覽
  • 日本陣發性睡眠性血尿症治療市場：依給藥途徑分析市場波動
  • 日本陣發性睡眠性血尿症治療藥物市場：按給藥途徑分類的銷售收入
  • 腸外
    • 靜脈輸液
    • 皮下注射
  • 口服

第6章：日本陣發性睡眠性血尿症治療市場：依最終用途分類的估算與趨勢分析

  • 日本陣發性睡眠性血尿症治療市場：依最終用途分類的概覽
  • 日本陣發性睡眠性血尿症治療市場：基於最終用途的波動分析
  • 日本陣發性睡眠性血尿症治療市場：依最終用途分類的銷售收入
  • 醫院和專科診所
  • 居家醫療環境
  • 其他

第7章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • Key customers
    • Key company market share analysis, 2025
    • AstraZeneca
    • Apellis Pharmaceuticals
    • BioCryst Pharmaceuticals
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc.
    • Regeneron Pharmaceuticals
    • Sanofi
    • Pfizer Inc.
    • Johnson & Johnson
Product Code: GVR-4-68040-890-0

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Summary

The Japan paroxysmal nocturnal hemoglobinuria treatment market size was valued at USD 279.95 million in 2025 and is projected to reach USD 455.53 million by 2033, growing at a CAGR of 5.88% from 2026 to 2033. This growth is driven by continuous advancements in complement inhibitor therapies, including the development of next-generation C3 and Factor B/D inhibitors that improve clinical outcomes and address unmet needs such as residual anemia.

Additionally, strong reimbursement policies and orphan drug incentives in Japan are supporting patient access to high-cost therapies and encouraging pharmaceutical innovation. Increasing disease awareness and improved diagnostic capabilities are also contributing to earlier detection and treatment, further expanding the treated patient population and sustaining market growth.

The market is primarily driven by significant advancements in complement inhibitor therapies that directly target the underlying mechanism of complement-mediated hemolysis. The transition from supportive care approaches, such as transfusions and anticoagulation, to targeted biologics has transformed clinical outcomes. Real-world evidence highlights this shift, as reported in February 2026 in the International Journal of Hematology, where 86.7% of 45 Japanese patients were treated with C5 inhibitors, resulting in a median increase in hemoglobin from 7.2 g/dL at diagnosis to 10.0 g/dL during treatment.

Innovation within the market is further strengthened by the evolution from first-generation C5 inhibitors to next-generation therapies, including upstream complement inhibitors targeting C3 and alternative pathway factors. These advancements address residual anemia associated with extravascular hemolysis, an unmet need in earlier treatments. A September 2025 review published in Drugs highlighted phase III trial data involving 441 patients, demonstrating that ravulizumab was non-inferior to eculizumab at 26 and 52 weeks. Additionally, findings from the APPLY-PNH and APPOINT-PNH trials showed that oral iptacopan delivered sustained reductions in hemolysis markers and improved hemoglobin levels compared with continued anti-C5 therapy, signaling a shift toward more comprehensive, patient-friendly treatment options.

Japan's strong healthcare framework plays a crucial role in market expansion, particularly through universal coverage and supportive orphan drug policies. The government's reimbursement system, which covers approximately 70% of medical costs, ensures broad access to high-cost biologics and promotes early treatment initiation. Regulatory support further accelerates innovation, with orphan drugs receiving priority review timelines of around 9 months compared to the standard 12-month pathways. These incentives have attracted both global and domestic players, fostering a robust pipeline of advanced therapies and reinforcing Japan as a key market for the development of rare disease treatments.

Increasing diagnosis rates and disease awareness are also contributing significantly to market growth. Improved use of high-sensitivity flow cytometry and standardized diagnostic protocols has enhanced early detection of PNH, particularly among patients with aplastic anemia. An October 2024 MDPI publication reported that PNH clones were identified in 40-60% of patients, with untreated mortality exceeding 35% within 5 years, underscoring the importance of timely diagnosis. Additionally, a March 2024 study in the International Journal of Hematology involving 59 Japanese patients on C5 inhibitors reported a mean hemoglobin level of 10.2 g/dL, highlighting persistent symptom burden and the need for continued therapeutic optimization. Together, these factors are expanding the diagnosed patient population and sustaining long-term growth in the Japan PNH treatment market.

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the Japan paroxysmal nocturnal hemoglobinuria treatment market on the basis of action of mechanism, route of administration, and end use:

  • Action of Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
  • Complement Inhibitors
    • C5 Inhibitors
    • C3 Inhibitors
  • Supportive Care
    • Blood Transfusions
    • Immunosuppressant drugs
    • Anticoagulants
    • Others
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Parenteral
    • Intravenous (IV) Infusion
    • Subcutaneous (SC) Injection
  • Oral
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Specialty Clinics
  • Home Care Settings
  • Others

Table of Contents

Chapter 1. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Action of Mechanism Method
      • 1.1.1.2. Route of Administration Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Action of Mechanism Snapshot
  • 2.3. Route of Administration Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Restraint Analysis
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Action of Mechanism Estimates & Trend Analysis

  • 4.1. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Action of Mechanism Dashboard
  • 4.2. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Action of Mechanism Movement Analysis
  • 4.3. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market by therapy, Revenue
  • 4.4. Complement Inhibitors
    • 4.4.1. Complement Inhibitors market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. C5 Inhibitors
      • 4.4.2.1. C5 Inhibitors market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. C3 Inhibitors
      • 4.4.3.1. C3 Inhibitors market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Supportive Care
    • 4.5.1. Supportive Care market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2. Blood Transfusions
      • 4.5.2.1. Blood Transfusions market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3. Immunosuppressant
      • 4.5.3.1. Immunosuppressant drugs market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.4. Anticoagulants
      • 4.5.4.1. Anticoagulants market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Route of Administration Dashboard
  • 5.2. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Route of Administration Movement Analysis
  • 5.3. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Route of Administration, Revenue
  • 5.4. Parenteral
    • 5.4.1. Parenteral market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Intravenous (IV) Infusion
      • 5.4.2.1. Intravenous (IV) Infusion market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Subcutaneous (SC) Injection
      • 5.4.3.1. Subcutaneous (SC) Injection market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: End Use Dashboard
  • 6.2. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market: End Use Movement Analysis
  • 6.3. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market by End Use, Revenue
  • 6.4. Hospitals & Specialty Clinics
    • 6.4.1. Hospitals & Specialty Clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Home Care Settings
    • 6.5.1. Home Care Settings market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2025
    • 7.3.4. AstraZeneca
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Action of Mechanism benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Apellis Pharmaceuticals
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Action of Mechanism benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. BioCryst Pharmaceuticals
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Action of Mechanism benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Novartis AG
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Action of Mechanism benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. F. Hoffmann-La Roche Ltd
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Action of Mechanism benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Amgen Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Action of Mechanism benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Regeneron Pharmaceuticals
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Action of Mechanism benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Sanofi
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Action of Mechanism benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Pfizer Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Action of Mechanism benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Johnson & Johnson
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Action of Mechanism benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market, By Action of Mechanism, 2021 - 2033 (USD Million)
  • Table 4 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 5 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market, By End-Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Japan paroxysmal nocturnal hemoglobinuria treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment.
  • Fig. 8 Market formulation & validation
  • Fig. 9 Japan paroxysmal nocturnal hemoglobinuria treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Japan paroxysmal nocturnal hemoglobinuria treatment market: Action of Mechanism movement analysis
  • Fig. 14 Japan paroxysmal nocturnal hemoglobinuria treatment market: Action of Mechanism outlook and key takeaways
  • Fig. 15 Complement Inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 C5 Inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 C3 Inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Supportive Care market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Blood Transfusions market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Immunosuppressant drugs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Anticoagulants market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Japan paroxysmal nocturnal hemoglobinuria treatment market: Route of Administration movement analysis
  • Fig. 24 Japan paroxysmal nocturnal hemoglobinuria treatment market: Route of Administration outlook and key takeaways
  • Fig. 25 Parenteral market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Intravenous (IV) Infusion market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Subcutaneous (SC) Injection market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Oral market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Japan paroxysmal nocturnal hemoglobinuria treatment market: End Use movement analysis
  • Fig. 30 Japan paroxysmal nocturnal hemoglobinuria treatment market: End Use outlook and key takeaways
  • Fig. 31 Hospitals & Specialty Clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Home Care Settings market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Market share of key market players- Japan paroxysmal nocturnal hemoglobinuria treatment market